RAUTENSIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RAUTENSIN (RAUTENSIN).
Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.
| Metabolism | Extensively metabolized in the liver via deacetylation and hydrolysis; reserpine is metabolized by CYP3A4 and carboxyl esterase. |
| Excretion | Rautensin (rauwolfia alkaloids) is primarily excreted via hepatic metabolism and biliary-fecal elimination, with less than 1% excreted unchanged in urine. Renal excretion accounts for approximately 10% of metabolites, while biliary/fecal elimination accounts for approximately 90%. |
| Half-life | The terminal elimination half-life of rauwolfia alkaloids is approximately 50-100 hours, with a mean of about 72 hours. This long half-life supports once-daily dosing and leads to slow accumulation and sustained antihypertensive effect. |
| Protein binding | Protein binding is approximately 50-60%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 1.6 L/kg, indicating extensive tissue distribution and accumulation in adipose tissue. This high Vd contributes to the long half-life. |
| Bioavailability | Oral bioavailability is variable, estimated at approximately 50-60% due to extensive first-pass hepatic metabolism. Bioavailability is route-specific: oral only, as no parenteral formulations are clinically available. |
| Onset of Action | Onset of action after oral administration is delayed, typically occurring within 1-2 weeks of continuous therapy. Maximal antihypertensive effect may require 3-6 weeks. |
| Duration of Action | The duration of action after discontinuation of therapy is prolonged, with antihypertensive effects persisting for several weeks due to slow elimination. Gradual withdrawal is recommended to avoid rebound hypertension. |
1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 50%; GFR <30 mL/min: contraindicated due to thiazide component. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for use in children; safety and efficacy not established. |
| Geriatric use | Start at lowest dose (0.5 tablet once daily); monitor for hypotension and electrolyte imbalance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RAUTENSIN (RAUTENSIN).
| Breastfeeding | Reserpine is excreted into breast milk. M/P ratio: approximately 1:1. Potential for serious adverse effects in the nursing infant, including respiratory depression, bradycardia, and gastrointestinal disturbances. Breastfeeding is not recommended during maternal therapy with Rautensin. |
| Teratogenic Risk | Rautensin contains reserpine and other rauwolfia alkaloids. Reserpine crosses the placenta. First trimester: limited data, but animal studies suggest potential for fetal harm (neural tube defects, cardiovascular anomalies) at high doses. Second and third trimesters: risk of neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to catecholamine depletion. Avoid use during pregnancy, especially after 20 weeks gestation. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Active peptic ulcer (may exacerbate)","History of electroconvulsive therapy","Parkinsonism","Depression (especially with suicidal tendencies)"]
| Precautions | ["May cause mental depression, especially in patients with history of depression","Use caution in patients with gastric ulcers (may increase gastric acid secretion)","Avoid in patients undergoing electroconvulsive therapy (ECT)","May cause hypotension and bradycardia","Discontinue 2 weeks before elective surgery"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate frequently. Assess fetal growth and amniotic fluid volume via ultrasound if used in second or third trimester. Monitor neonate for respiratory depression, bradycardia, hypotonia, and poor feeding after delivery if maternal exposure occurred late in pregnancy. |
| Fertility Effects | Reserpine may impair male and female fertility due to its effects on catecholamine metabolism and hormonal regulation. In animal studies, reserpine caused decreased spermatogenesis and disrupted estrous cycles. Clinical relevance in humans is unclear but caution advised in patients attempting conception. |